Wydanie 3/2009
str. 13

Aktualne wytyczne diagnostyczno-terapeutyczne dotyczące postępowania w przypadkach pacjentów z wysiękową postacią AMD

Current Diagnostic and Therapeutic Guidelines for Wet AMD Management

Andrzej Stankiewicz, Małgorzata Figurska

Klinika Okulistyki Wojskowego Instytutu Medycznego w Warszawie Kierownik: prof. dr hab. n. med. Andrzej Stankiewicz


Summary: Historically in wet AMD treatment we usually used radiation therapy, laser photocoagulation or surgical procedures. Now is the time for pharmacological approaches such as photodynamic therapy with Visudyne and anti-VEGF factors. Based on knowledge that VEGF factors are responsible for CNV development and progression and on the success of anti-angiogenic therapies in the treatment of tumors anti-VEGF A drugs are used as therapies for wet AMD. Based on multi-centre randomized clinical studies, the article presents current diagnostic and therapeutic guidelines for wet AMD, indications and exclusion criteria for laser therapy, photodynamic therapy, pegaptanib sodium and ranibizumab therapy, reinjections criteria and monitoring treatment effects. Intravitreal ranibizumab injections have FDA and EMEA recommendations for wet AMD treatment, because Lucentis is the first drug for intraocular use, which offers patients with wet AMD the opportunity to maintain and improve vision.

Słowa kluczowe: wysiękowa postać zwyrodnienia plamki związanego z wiekiem (ang. AMD), laseroterapia, pegaptanib sodu, ranibizumab, terapia fotodynamiczna, terapia łączona.

Keywords: wet form of age-related macular disease (AMD), laser therapy, pegaptanib sodium, ranibizumab, photodynamic therapy, combination therapy.


powrót

REDAKCJA NIE UDZIELA PORAD MEDYCZNYCH I NIE POŚREDNICZY W KONSULTACJACH PACJENTÓW Z LEKARZAMI